E. Ohman J:or Asset Management 13F: Adds $25M to VRTX Stake

E. Ohman J:or Asset Management boosted its stake in Vertex Pharmaceuticals Incorporated (NasdaqGS: VRTX) by 552.3% during the third quarter, according to a Form 13F filing with the U.S. Securities and Exchange Commission on October 22, 2026. The firm added 48,731 shares to bring its total holding to 57,554 shares. The updated position carried a reported value of $30,089,807 as of the filing date.

VRTX Vertex Pharmaceuticals Incorporated

$535.17 ▲ +18.37% year to date

1M 3M YTD

Daily close · Oct 22, 2026

What Changed in E. Ohman J:or Asset Management's Vertex Pharmaceuticals Position

The asset management firm significantly expanded its bet on the biotechnology developer, growing its share count from a previous total of 8,823 shares up to 57,554 shares. That triple-digit percentage jump reflects a much larger commitment to the Boston-based drugmaker.

Other Institutional Activity in Vertex Pharmaceuticals

Other institutional investors also shifted their holdings in Vertex Pharmaceuticals recently. Livforsakringsbolaget Skandia grew its holdings by 21,920 shares, ending with 27,700 shares worth about $14,481,837. Covea Finance held 15,000 shares worth roughly $7,842,150. Meanwhile, Capital International Investors trimmed its stake by 431,119 shares to hold 4,695,144 shares valued at $2,512,700,134.

Vertex Pharmaceuticals Incorporated Stock Up 1.2%

Vertex Pharmaceuticals shares recently traded around $530.98 on October 22, 2026, sitting 0.8% below the closing price of $535.17 on the filing date. The stock trades above both its 50-day moving average of $522.37 and its 200-day moving average of $476.84.

Recent Earnings

Vertex Pharmaceuticals reported $12.59 billion in trailing-twelve-month revenue alongside earnings of $17.27 per share. The company posted a net profit margin of 35.0% and a return on equity of 23.5%. Revenue grew 12.5% compared to the same period last year. Investors look ahead to the next earnings release scheduled for November 2, 2026.

Insider Buying and Selling at Vertex Pharmaceuticals Incorporated

Company insiders completed several transactions in recent months. Officer Carmen Bozic sold 596 shares on June 26, 2026, at $482.50 per share for a total value of $287,570. Officer Joy Liu sold 828 shares on July 1, 2026, at $502.71 per share worth $416,244. Officer Duncan J. Mckechnie disposed of 1,541 shares on July 2, 2026, at $519.00 apiece for $799,779. Officer Ourania Tatsis also sold 1,500 shares on July 2, 2026, at $524.99 per share totaling $787,485.

Analysts Set New Price Targets

Wall Street research firms updated their outlooks on the stock over the summer and fall. TD Cowen maintained a buy rating while lifting its target from $525.00 to $550.00 on August 4, 2026. Truist Securities kept a buy rating on August 5, 2026, moving its target from $560.00 to $565.00. Barclays maintained an overweight rating on August 5, 2026, raising its target from $615.00 to $617.00. UBS kept a buy rating on September 28, 2026, nudging its target from $585.00 to $615.00. RBC Capital maintained an outperform rating on October 8, 2026, raising its target to $576.00 from $570.00. Overall, the stock carries a consensus buy recommendation from 28 analysts with a mean price target of $571.46.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated operates as a biotechnology enterprise focused on developing and commercializing transformative medicines for severe specialty illnesses. Its core portfolio treats conditions such as cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain.

Bottom Line

Institutional interest in the biotechnology firm remains active as investors await the upcoming earnings report on November 2, 2026. Monitoring upcoming regulatory updates and sales figures for its cystic fibrosis and pain treatments will help clarify the company's growth trajectory.